Search results for "Treatment-Resistant"

showing 9 items of 19 documents

Real-world evidence from a European cohort study of patients with treatment resistant depression:Healthcare resource utilization

2022

Journal of affective disorders 298, Part A 442-450 (2022). doi:10.1016/j.jad.2021.11.004 special issue: "Special Issue on Corona Virus / Edited by Allan Young, Ron Acierno, Xiang Yang Zhang"

Healthcare resource utilization Major depressive disorder Observational study Real-world evidence Treatment resistant depressionmedicine.medical_specialtyMajor depressive disorderTreatment resistant depressionCohort StudiesIndirect costsDepressive Disorder Treatment-ResistantHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depressionObservational studyHealth careHealthcare resource utilizationmedicineHumansMajor depressive episodeDepression (differential diagnoses)Retrospective StudiesReal-world evidenceDepressive DisorderDepressive Disorder Majorbusiness.industryTreatment-ResistantMajorHealth Care Costsmedicine.diseasePsychiatry and Mental healthClinical PsychologyEmergency medicineMajor depressive disorderObservational studymedicine.symptombusinessHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depression; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Retrospective Studies; Depressive Disorder Major; Depressive Disorder Treatment-ResistantTreatment-resistant depressionDelivery of Health CareCohort study
researchProduct

Relationship between childhood physical abuse and clinical severity of treatment-resistant depression in a geriatric population

2021

Introduction We assessed the correlation between childhood maltreatment (CM) and severity of depression in an elderly unipolar Treatment-Resistant Depression (TRD) sample. Methods Patients were enrolled from a longitudinal cohort (FACE-DR) of the French Network of Expert TRD Centres. Results Our sample included 96 patients (33% of the overall cohort) aged 60 years or above, with a mean age of 67.2 (SD = 5.7). The majority of the patients were female (62.5%). The Montgomery and Asberg Depression Rating Scale (MADRS) and Quick Inventory Depression Scale-Self Report (QIDS-SR) mean scores were high, 28.2 (SD = 7.49) [MADRS score range: 0–60; moderate severity≥20, high severity≥35] and 16.5 (SD…

MaleEpidemiologyEmotionsSocial SciencesCriminologyPediatricsSeverity of Illness IndexGeriatric DepressionDepressive Disorder Treatment-Resistant0302 clinical medicineSociologyAdverse Childhood ExperiencesMedicine and Health SciencesPsychologyPublic and Occupational HealthChild AbuseDepression (differential diagnoses)Aged 80 and overeducation.field_of_studySchoolsMultidisciplinaryDepression[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyTraumatic Injury Risk FactorsQRMiddle AgedPhysical abuseCohortMedicineFemaleCrimeFranceResearch ArticlePersonalitymedicine.medical_specialtyPsychometricsScienceGeriatric PsychiatryPopulationEducation03 medical and health sciencesRating scaleGeriatric populationInternal medicineMental Health and PsychiatrymedicineHumanseducationAgedPersonality TraitsPsychiatric Status Rating ScalesDepressive Disorder MajorMood Disordersbusiness.industryCTQ treeBiology and Life Sciencesmedicine.disease030227 psychiatryHealth CareGeriatricsMedical Risk Factors[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieGeriatric CareSelf ReportbusinessTreatment-resistant depression030217 neurology & neurosurgery
researchProduct

Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the rea…

2022

Abstract Background Tobacco smoking has been associated with suicide, impulsivity and depression in non-clinical populations with differences across sexes. Objective To determine the role of tobacco smoking in Treatment-Resistant Depression (TRD) according to sex in a precision-medicine approach. Method The FACE-TRD cohort is a national cohort of TRD patients recruited in 13 resistant depression expert centers between 2014 and 2021 and followed-up at 6 months. A standardized one-day long comprehensive battery was carried out, including trained-clinician and patient-reported outcomes, and patients were reevaluated at 6 months on their smoking and psychiatric hospitalization outcomes. Results…

Malemedicine.medical_treatmentMESH: Tobacco SmokingSuicide AttemptedtobaccoMESH: NicotineCohort StudiesDepressive Disorder Treatment-Resistantchemistry.chemical_compoundSurveys and QuestionnairesMedicinePrecision MedicineVareniclineMESH: Cohort StudiesDepression (differential diagnoses)health care economics and organizationseducation.field_of_studypublic mental healthMESH: Middle AgedMESH: Suicidal Ideationpublic healthMiddle AgedMESH: Smoking CessationpsychiatryCohortdepressionMESH: Suicide AttemptedFemalemental healthNicotinemedicine.medical_specialtyPopulationeducationMESH: Precision MedicinesmokingSuicidal IdeationMESH: Depressive Disorder Treatment-ResistantSex FactorsMESH: Sex FactorsTobacco SmokingHumansMESH: Surveys and QuestionnaireseducationPsychiatryBiological PsychiatryPharmacologyMESH: HumansSuicide attemptbusiness.industryOdds ratiomedicine.diseaseMESH: Maleschizophreniachemistry[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthSmoking cessationSmoking CessationbusinessTreatment-resistant depressionMESH: Female
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes.

2021

Abstract Background Treatment resistant depression (TRD) characterizes a subgroup of 10–30% of patients with major depressive disorder, and is associated with considerable morbidity and mortality. A consensus treatment for TRD does not exist, which often leads to wide variations in treatment strategies. Real-world studies on treatment patterns and outcomes in TRD patients in Europe are lacking and could help elucidate current treatment strategies and their efficacy. Methods This non-interventional cohort study of patients with TRD (defined as treatment failure on ≥2 oral antidepressants given at adequate dose and duration) with moderate to severe depression collected real-world data on trea…

Moderate to severemedicine.medical_specialtyMEDLINEAntidepressive Agents; Cohort Studies; Europe; Humans; Depressive Disorder Major; Depressive Disorder Treatment-ResistantReal world evidenceTreatment failureCohort Studies03 medical and health sciencesDepressive Disorder Treatment-Resistant0302 clinical medicineInternal medicinemedicineHumansPsiquiatriaDepression (differential diagnoses)Depressive DisorderDepressive Disorder Majorbusiness.industryTreatment-ResistantMajormedicine.diseaseAntidepressive Agents030227 psychiatryEuropePsychiatry and Mental healthClinical PsychologyMajor depressive disorderbusinessTreatment-resistant depression030217 neurology & neurosurgeryCohort studyJournal of affective disorders
researchProduct

Novel Drug Delivery System for Treatment-Resistant Schizophrenia

2021

Settore CHIM/09 - Farmaceutico Tecnologico Applicativotreatment-resistant schizophrenia clozapine oral transmucosal delivery solid dosage form unidirectional delivery sustained release profile
researchProduct

Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients

2019

The study aims to investigate: (1) the prevalence of cannabis among epileptic patients seen at Mansoura University Hospital, (2) serum levels and gene expression of cytokines in epilepsy patients and the controls. and (3) the possibility that cannabis use affects the cytokine levels in epilepsy patients, triggering its future use in treatment. We recruited 440 epilepsy patients and 200 controls matched for age, gender, and ethnicity. Of the epileptic patients, 37.5% demonstrated lifetime cannabis use with a mean duration of 15 &plusmn

cannabismedicine.medical_specialtypurified cannabidiol (cbd)inflammatory cytokinesmedicine.medical_treatmenttreatment-resistant epilepsyArticlelcsh:RC321-571Proinflammatory cytokine03 medical and health sciencesEpilepsy0302 clinical medicineInternal medicinemedicineanticonvulsant drugslcsh:Neurosciences. Biological psychiatry. Neuropsychiatryseizures030304 developmental biology0303 health sciencesbiologybusiness.industryGeneral NeuroscienceInterleukintetrahydrocannabinol (thc)Cannabis useUniversity hospitalbiology.organism_classificationmedicine.diseaseCytokineepilepsyTumor necrosis factor alphaCannabisbusiness030217 neurology & neurosurgeryBrain Sciences
researchProduct

Childhood maltreatment and clinical severity of treatment‐resistant depression in a French cohort of outpatients (FACE‐DR): One‐year follow‐up

2020

International audience; Childhood maltreatment is associated with major depressive disorder (MDD). It not only increases the risk of lifetime MDD, but it also aggravates its course. Among depressed patients, 20-30% of them experience treatment-resistance depression (TRD). We aimed to assess the association between childhood maltreatment, severity of depression in a unipolar TRD sample, and patient outcomes after one-year of follow-up. Methods: Patients were recruited for a prospective cohort from the French network of TRD expert centers. Depressive symptom severity was assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology se…

medicine.medical_specialtyDepressive disordersMESH: DepressionPopulationMESH: Depressive Disorder MajorPoison controlChildhood trauma03 medical and health sciences0302 clinical medicineInternal medicineSurveys and QuestionnairesMESH: ChildOutpatientsmedicineHumansChild AbuseProspective StudiesMESH: Surveys and QuestionnaireseducationProspective cohort studyChildChildhood neglecteducation.field_of_studyDepressive Disorder Major[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsMESH: Humansbusiness.industryDepressionAntidepressant responseChildhood abuseCTQ treeMESH: Follow-Up StudiesMESH: Child Abusemedicine.diseaseMESH: Prospective Studies3. Good health030227 psychiatryMESH: OutpatientsPsychiatry and Mental healthClinical PsychologySexual abuse[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthCohortMajor depressive disorderTreatment-resistant depressionbusinessTreatment-resistant depression030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Effects of High Frequency Repetitive Transcranial Magnetic Stimulation (HF-rTMS) on Delay Discounting in Major Depressive Disorder: An Open-Label Unc…

2019

Background: Delay discounting (DD) refers to the decrease of a present subjective value of a future reward as the delay of its delivery increases. Major depressive disorder (MDD), besides core emotional and physical symptoms, involves difficulties in reward processing. Depressed patients often display greater temporal discounting rates than healthy subjects. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique applied in several countries to adult patients with treatment resistant depression. Studies suggest that this technique can be used to modulate DD, but no trial has assessed its effects on depressed patients. Methods: In this open-label unc…

medicine.medical_specialty[SDV]Life Sciences [q-bio]medicine.medical_treatmentimpulsivityAudiologyImpulsivitybehavioral disciplines and activitiesArticlelcsh:RC321-57103 medical and health sciences0302 clinical medicinemental disordersmedicineTemporal discountinglcsh:Neurosciences. Biological psychiatry. Neuropsychiatrydelay discountingmajor depressive disorderbusiness.industryGeneral Neurosciencerepetitive transcranial magnetic stimulationhigh frequency repetitive transcranial magnetic stimulationCognitionmedicine.disease030227 psychiatry3. Good healthDorsolateral prefrontal cortexTranscranial magnetic stimulationmedicine.anatomical_structure[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthBrain stimulationMajor depressive disordermedicine.symptombusinessTreatment-resistant depression030217 neurology & neurosurgeryBrain Sciences
researchProduct

Treatment-resistant depression in a real-world setting: first interim analysis of characteristics, healthcare resource use, and utility values of the…

2020

Background: Major depressive disorder (MDD) is among the most common psychiatric disorders. One-third of patients are usually unresponsive to several lines of treatment. This study aimed to describe the FondaMental French cohort of patients with treatment-resistant depression (TRD) and to estimate utility and healthcare resource use outcomes. Methods: Patients with TRD were evaluated prospectively over four years (baseline, 6, 12, 18, 24, 36 and 48 months) in a real-world clinical setting. Interim analyses focused on the first two consecutive years. Four MDD-related states (major depressive episode (MDE), response, remission, recovery) were defined based on the MADRS (Montgomery&ndash

medicine.medical_specialtyreal-world[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthArticlelcsh:RC321-57103 medical and health sciences0302 clinical medicinehealthcare resource useQuality of lifeRating scaleInternal medicineMedicine[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Major depressive episodelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryDepression (differential diagnoses)business.industryGeneral Neurosciencemedicine.diseaseInterim analysis3. Good health030227 psychiatryutility[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthCohorttreatment-resistant depressionMajor depressive disorder[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC][SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.symptombusinessTreatment-resistant depression030217 neurology & neurosurgery
researchProduct